Medical Tidbits,Cordis Announces Return to the Drug-Eluting Stent Market

medical device news

PRNewswire/ — Cardinal Health today announced that it has entered into a distribution agreement with Biosensors that enables Cordis, Cardinal Health’s interventional vascular business, to sell Biosensors’ coronary stent portfolio. Cordis will sell Biosensors’ coronary stents in select countries in Europe, the Middle East, Africa, Australia and New Zealand. This marks Cordis’ return to the drug-eluting stent (DES) market and the beginning of a long-term partnership between Cardinal Health and Biosensors to further leverage their respective distribution capabilities in select regions read more

Alprolix® (rFIXFc) approved in the EU for the treatment of haemophilia B

First Fc Fusion therapy approved for haemophilia B in the EU to provide extended protection against bleeds

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Biogen (NASDAQ: BIIB) today announced that the European Commission (EC) has approved Alprolix® (rFIXFc), their extended half-life therapy, for the treatment of haemophilia B in all 28 European Union (EU) member states and maintained its orphan designation. Alprolix is the only recombinant factor IX Fc Fusion protein therapy for haemophilia B to offer people in the EU prolonged protection against bleeding episodes with fewer prophylactic injections. read more

Boston Cancer Support to receive ASTRO Survivor Circle grant

The American Society for Radiation Oncology (ASTRO) has selected a Boston-based organization, Boston Cancer Support, to receive one of two 2016 ASTRO Survivor Circle grants. The organization will receive $8,500 for its work supporting those who have been touched by cancer, including patients, friends, caregivers or healthcare professionals, through its website, www.bostoncancersupport.org , and its two community programs. The group will be in attendance at ASTRO’s 58th Annual Meeting, September 25-28, 2016, in Boston at the Boston Convention and Exhibition Center.

Oncology Ventures DRP for identification of patients who benefit from 5-FU treatment – data published in PLOS ONE

Hoersholm, Denmark; May 12th, 2016 – Oncology Venture Sweden AB (OV:ST) announces that positive data on the in-licensed technology from Medical Prognosis Institute, the Drug Response Predictor (DRP), has been published in the scientific journal PLOS ONE with the title: “Cell line derived 5-FU and irinotecan drug-sensitivity profiles evaluated in adjuvant colon cancer trial data”. Data from a prospective randomized clinical trial was analyzed with the unique DRP™ tool. The DRP for 5-FU could identify which patients benefitted from treatment with 5-FU. When looking at overall survival the patients with the most positive predictor have twice the survival rate of the patients with poor prediction. read more

Allergan and Gedeon Richter Plc. to Present Data on Cariprazine at the American Psychiatric Association (APA) Annual Meeting

PRNewswire/ — Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that nine posters highlighting additional scientific data and clinical research on cariprazine, an atypical antipsychotic, will be presented during the upcoming American Psychiatric Association Annual Meeting in Atlanta, GA, May 14 to May 18, 2016.

“Advancing scientific discovery and addressing unmet clinical needs are at the heart of Allergan’s Open Science approach,” said Dr. David Nicholson, President & Executive Vice President, Global R&D at Allergan. “The abstracts presented at APA underscore the safety and efficacy of cariprazine, and investigated its potential to provide additional therapeutic benefits for the treatment of bipolar depression and the negative symptoms of schizophrenia.” read more

Celldex Stumble Makes Space for OncBioMune at Head of Cancer Vaccines

PRNewswire/ – Developing cancer vaccines, a type of immunotherapy, has been notoriously difficult in the past, but not impossible.  Most notably, there are FDA approvals for three vaccines, although two, Gardasil and Cervarix, are preemptive in nature, fighting human papillomavirus (HPV) that often leads to cancer.  Gardasil, a product of Merck subsidiary Merck Sharp & Dohme Corp., is a vaccine that protects against four different types of HPV, namely in girls and young women (and males with anal cancer) in helping to prevent cervical, vaginal, vulvar and anal cancers. GlaxoSmithKline’s Cervarix is indicated for girls and young women for the prevention of certain diseases cause by oncogenic HPV (types 16 and 18), including cervical cancer, adenocarcinoma and different grades of abnormal cell growth that can lead to cervical cancer (cervical intraepithelial neoplasia).  read more

Phenomenome Discoveries Announces the Successful Validation of OvAware™, a Simple Blood Test for the Early Detection of Ovarian Cancer

Early detection seen as key to reducing mortality

Using its proprietary metabolomics technology, Phenomenome Discoveries Inc. had previously discovered that specific metabolic abnormalities were present in the blood of women suffering from ovarian cancer.  The company has subsequently developed a simple test (OvAware™) that can be performed on a single drop of blood.  The performance of the test has now been verified in two large studies – one in Japan (99 controls and 112 ovarian cancer patients) led by Dr. Fumio Nomura, MD, Chiba, Japan and one in Canada (1041 controls and 325 ovarian cancer patients) led by Dr. Walter Gotlieb, MD, PhD, Montreal, Canada.  In both studies, the blood test was able to detect ovarian cancer with 97% accuracy.  The results of these studies will be presented by Dr. Dayan Goodenowe, Founder, President and CEO, Phenomenome Discoveries at the Cancer Diagnostics Conference and Expo in Rome, Italy on June 13th, 2016. The results of the studies and more information about the science behind the test can be found at the company’s website: http://www.phenomenome.com

International Trade Commission to Investigate Chinese Manufacturer BMC Medical’s Infringement of ResMed Patents

PRNewswire/ — ResMed (NYSE:RMD) the world’s leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care, announced today that the United States International Trade Commission (ITC) has accepted its request to investigate alleged infringement of its patented technology by Chinese medical device manufacturer BMC Medical Co., Ltd. and its U.S. distributor, 3B Medical. read more

Pioneering global regenerative medical technology company, Tissue Regenix Group plc,  officially opens new Leeds site

LEEDS, England–(BUSINESS WIRE)–Tissue Regenix Group plc is pleased to announce the official opening of its new Leeds-based manufacturing centre. This opening is the culmination of a merger between the York and Leeds sites and brings together the full weight of Tissue Regenix capabilities, in this newly renovated multi-functional facility. The pioneering medical technology company – which uses biological (human and animal) materials to make replacement human tissues – has a strong Leeds-based heritage, having begun at The University of Leeds, and now boasts offices and partners across the US, EU and South America. read more

 

 

 

Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.